US Bancorp
OBIO icon

US Bancorp’s Orchestra BioMed OBIO Stock Holding History

US Bancorp’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$883 Buy
+142
New +$681 ﹤0.01% 4058

Other funds holding OBIO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
Daytona Street Capital
Daytona Street Capital Saint Louis, Missouri $141M AUM 14.38% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Holos Integrated Wealth
Holos Integrated Wealth Kennett Square, Pennsylvania $223M AUM 9.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

US Bancorp's OBIO Position: Q3 2026 in Review

US Bancorp opened a new position in Orchestra BioMed (OBIO) in Q3 2026: 142 shares worth $883. The stake represents ﹤0.01% of the portfolio and ranks #4058 among its holdings.

28 funds tracked by Wall St. Rank hold OBIO as of Q3 2026.

  • US Bancorp held 142 shares of Orchestra BioMed worth $883 as of Q3 2026.
  • Orchestra BioMed was a new US Bancorp position in Q3 2026.
  • Orchestra BioMed made up ﹤0.01% of US Bancorp's portfolio in Q3 2026, its #4058 holding.
  • 28 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2026.

Based on US Bancorp's 13F filing for Q3 2026, filed 5 Nov 2026.